CELC · Celcuity Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Celcuity Inc. launched ReftraPIC on September 30th; 78% of its top 36 accounts ordered, and 91% of U.S. commercial and Medicare lives are covered. No third-quarter product revenue was recognized; cash, cash equivalents, and short-term investments reached $642.7 million.
Celcuity launched REVTORPYK after FDA approval for adults with HR+/HER2- ABC without a PIK3CA mutation, but recognized no product revenue through September 30, 2026; its nine-month net loss was $205.0 million.
Celcuity Inc. launched REVTORPYK on September 30, 2026, with 91% of U.S. commercial and Medicare lives covered; third-quarter net loss was $73.3 million, and no product revenue was recognized.
Celcuity Inc. appointed David W. Gryska to its expanded nine-member Board effective October 1, 2026, and to its Audit and Compensation Committees, with a $70,000 annual cash retainer, $100,000 annual equity award, and 893 restricted stock units.
Celcuity launched REVTORPYK (gedatolisib) in the United States for eligible adults with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation detected after at least one line of metastatic endocrine therapy.